MQS Management LLC Buys New Shares in Edwards Lifesciences Co. (NYSE:EW)

MQS Management LLC bought a new stake in Edwards Lifesciences Co. (NYSE:EW) in the third quarter, HoldingsChannel.com reports. The firm bought 3,708 shares of the medical research company’s stock, valued at approximately $245,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EW. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences in the first quarter valued at $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences in the second quarter valued at $29,000. Webster Bank N. A. acquired a new stake in Edwards Lifesciences in the second quarter valued at $39,000. Versant Capital Management Inc raised its stake in Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after buying an additional 326 shares in the last quarter. Finally, HHM Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the second quarter valued at $55,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,250 shares of company stock valued at $2,744,438 in the last quarter. 1.29% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wells Fargo & Company cut their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group cut their target price on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Robert W. Baird cut their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, Truist Financial dropped their price target on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Price Performance

Shares of EW opened at $67.76 on Friday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The stock’s 50 day moving average is $67.42 and its two-hundred day moving average is $76.37. The firm has a market capitalization of $39.96 billion, a PE ratio of 9.78, a P/E/G ratio of 3.74 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.59 EPS. Research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.